| 前收市價 | 34.58 |
| 開市 | 33.83 |
| 買盤 | 33.68 x 30000 |
| 賣出價 | 34.26 x 30000 |
| 今日波幅 | 33.83 - 33.83 |
| 52 週波幅 | 28.95 - 42.65 |
| 成交量 | |
| 平均成交量 | 1 |
| 市值 | 4.576B |
| Beta 值 (5 年，每月) | 0.80 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.78 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 0.98 (2.87%) |
| 除息日 | 2022年12月01日 |
| 1 年預測目標價 | 51.00 |
- InvestorPlace
7 Perfect Presents to Gift Your 2023 Stock Portfolio
New Year 2023 will see a continued tightening of monetary policy as the Federal Reserve attempts to rein in sky-high inflation. Following the 50 basis point rate hike in Dec., there are expectations that Feb. and March will see 25 basis point rate hikes, respectively. That will bring target rates near 5% which is where investors should expect them to remain throughout 2023. In short, investors should expect 2023 to look and feel like 2022 in many ways. However, there are still a good deal of hot
- Benzinga
Perrigo Shares Fall As Investors React To Lowered FY22 Profit Guidance
Perrigo Company plc's (NYSE: PRGO) Q3 FY22 sales increased 5.5% Y/Y or 12.3%, excluding the impact of currency translation to $1.10 billion, almost in line with the consensus of $1.10 billion. The growth was led by the acquisition of HRA, strategic pricing actions across Consumer Self-Care segments, and cough/cold-related product sales. Adjusted EPS increased 24.4% to $0.56, up from $0.45 a year ago. "Although revenue growth in the quarter was robust, it was below our estimates due to unfavorabl
- Benzinga
FDA Postpones Review Meeting For First OTC Contraceptive Option From Perrigo
The FDA has pushed back a decision date on a proposed over-the-counter pill, Opill, from Perrigo Company plc's (NYSE: PRGO) subsidiary, HRA Pharma. Perrigo had previously expected approval in the first half of 2023, but the exact original FDA action date was never disclosed. Perrigo's HRA Pharma applied for the Rx-to-OTC switch on July 11, and such reviews typically take ten months. In addition to its decision delay, the FDA also postponed the planned joint meeting by its Nonprescription Drugs A
